Riegel v. Medtronic, Inc.
From Infogalactic: the planetary knowledge core
Riegel v. Medtronic, Inc. | |||||
---|---|---|---|---|---|
Argued December 4, 2007 Decided February 20, 2008 |
|||||
Full case name | Charles R. Riegel, et ux. v. Medtronic, Inc. | ||||
Docket nos. | 06-179 | ||||
Citations | 552 U.S. 312 (more) | ||||
Argument | Oral argument | ||||
Holding | |||||
The MDA’s pre-emption clause bars common-law claims challenging the safety or effectiveness of a medical device marketed in a form that received premarket approval from the FDA. | |||||
Court membership | |||||
|
|||||
Case opinions | |||||
Majority | Scalia, joined by Roberts, Kennedy, Souter, Thomas, Breyer, Alito (in full); Stevens (all except for III-A and III-B) | ||||
Concurrence | Stevens (in part) | ||||
Dissent | Ginsburg |
Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), is a United States Supreme Court case in which the Court held that the pre-emption clause of the Medical Device Amendment bars state common-law claims that challenges the effectiveness or safety of a medical device marketed in a form that received premarket approval from the Food and Drug Administration.
It modified the rule in Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996).
See also
- Eli Lilly & Co. v. Medtronic, Inc.
- FDA Preemption
- List of United States Supreme Court cases, volume 552
Further reading
- Syllabus and opinion in printable format from Justia.com
- Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>